Literature DB >> 21505102

Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias.

Brynn T Kvinlaug1, Wai-In Chan, Lars Bullinger, Mukundhan Ramaswami, Christopher Sears, Donna Foster, Stanley E Lazic, Rachel Okabe, Axel Benner, Benjamin H Lee, Inusha De Silva, Peter J M Valk, Ruud Delwel, Scott A Armstrong, Hartmut Döhner, D Gary Gilliland, Brian J P Huntly.   

Abstract

Fusion oncogenes in acute myeloid leukemia (AML) promote self-renewal from committed progenitors, thereby linking transformation and self-renewal pathways. Like most cancers, AML is a genetically and biologically heterogeneous disease, but it is unclear whether transformation results from common or overlapping genetic programs acting downstream of multiple mutations or by the engagement of unique genetic programs acting cooperatively downstream of individual mutations. This distinction is important, because the involvement of common programs would imply the existence of common molecular targets to treat AML, no matter which oncogenes are involved. Here we show that the ability to promote self-renewal is a generalized property of leukemia-associated oncogenes. Disparate oncogenes initiated overlapping transformation and self-renewal gene expression programs, the common elements of which were defined in established leukemic stem cells from an animal model as well as from a large cohort of patients with differing AML subtypes, where they strongly predicted pathobiological character. Notably, individual genes commonly activated in these programs could partially phenocopy the self-renewal function of leukemia-associated oncogenes in committed murine progenitors. Furthermore, they could generate AML following expression in murine bone marrow. In summary, our findings reveal the operation of common programs of self-renewal and transformation downstream of leukemia-associated oncogenes, suggesting that mechanistically common therapeutic approaches to AML are likely to be possible, regardless of the identity of the driver oncogene involved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21505102      PMCID: PMC3119437          DOI: 10.1158/0008-5472.CAN-11-0176

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors.

Authors:  Antonio Cozzio; Emmanuelle Passegué; Paul M Ayton; Holger Karsunky; Michael L Cleary; Irving L Weissman
Journal:  Genes Dev       Date:  2003-12-15       Impact factor: 11.361

3.  NetAffx Gene Ontology Mining Tool: a visual approach for microarray data analysis.

Authors:  Jill Cheng; Shaw Sun; Adam Tracy; Earl Hubbell; Joseph Morris; Venu Valmeekam; Andrew Kimbrough; Melissa S Cline; Guoying Liu; Ron Shigeta; David Kulp; Michael A Siani-Rose
Journal:  Bioinformatics       Date:  2004-02-12       Impact factor: 6.937

Review 4.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

5.  c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells.

Authors:  Jay L Hess; Claudia B Bittner; Deniz T Zeisig; Christian Bach; Uta Fuchs; Arndt Borkhardt; Jon Frampton; Robert K Slany
Journal:  Blood       Date:  2006-02-28       Impact factor: 22.113

6.  Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells.

Authors:  Julie Lessard; Guy Sauvageau
Journal:  Nature       Date:  2003-04-20       Impact factor: 49.962

7.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia.

Authors:  Lars Bullinger; Konstanze Döhner; Eric Bair; Stefan Fröhling; Richard F Schlenk; Robert Tibshirani; Hartmut Döhner; Jonathan R Pollack
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

8.  Bioconductor: open software development for computational biology and bioinformatics.

Authors:  Robert C Gentleman; Vincent J Carey; Douglas M Bates; Ben Bolstad; Marcel Dettling; Sandrine Dudoit; Byron Ellis; Laurent Gautier; Yongchao Ge; Jeff Gentry; Kurt Hornik; Torsten Hothorn; Wolfgang Huber; Stefano Iacus; Rafael Irizarry; Friedrich Leisch; Cheng Li; Martin Maechler; Anthony J Rossini; Gunther Sawitzki; Colin Smith; Gordon Smyth; Luke Tierney; Jean Y H Yang; Jianhua Zhang
Journal:  Genome Biol       Date:  2004-09-15       Impact factor: 13.583

9.  Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients.

Authors:  W-C Chou; C-Y Chen; H-A Hou; L-I Lin; J-L Tang; M Yao; W Tsay; B-S Ko; S-J Wu; S-Y Huang; S-C Hsu; Y-C Chen; Y-N Huang; M-H Tseng; C-F Huang; H-F Tien
Journal:  Leukemia       Date:  2009-02-19       Impact factor: 11.528

10.  Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.

Authors:  Piu Wong; Masayuki Iwasaki; Tim C P Somervaille; Chi Wai Eric So; Chai Wai Eric So; Michael L Cleary
Journal:  Genes Dev       Date:  2007-10-17       Impact factor: 11.361

View more
  29 in total

1.  Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors.

Authors:  Gregory J Gores; Scott H Kaufmann
Journal:  Genes Dev       Date:  2012-02-15       Impact factor: 11.361

2.  Emerging therapeutic aspects in oncology.

Authors:  David J Macewan
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

3.  Myeloid differentiation and the leukemia-initiating cell.

Authors:  D G Tenen
Journal:  Leuk Suppl       Date:  2014-12-17

4.  A quantitative proteomics approach identifies ETV6 and IKZF1 as new regulators of an ERG-driven transcriptional network.

Authors:  Ashwin Unnikrishnan; Yi F Guan; Yizhou Huang; Dominik Beck; Julie A I Thoms; Sofie Peirs; Kathy Knezevic; Shiyong Ma; Inge V de Walle; Ineke de Jong; Zara Ali; Ling Zhong; Mark J Raftery; Tom Taghon; Jonas Larsson; Karen L MacKenzie; Pieter Van Vlierberghe; Jason W H Wong; John E Pimanda
Journal:  Nucleic Acids Res       Date:  2016-09-06       Impact factor: 16.971

5.  Transcription factor 4 (TCF4) expression predicts clinical outcome in RUNX1 mutated and translocated acute myeloid leukemia.

Authors:  Florentien E M In 't Hout; Mylène Gerritsen; Lars Bullinger; Bert A van der Reijden; Gerwin Huls; Edo Vellenga; Joop H Jansen
Journal:  Haematologica       Date:  2019-12-19       Impact factor: 9.941

6.  PML-RARα co-operates with Sox4 in acute myeloid leukemia development in mice.

Authors:  Nader Omidvar; Mei Lin Maunakea; Letetia Jones; Sabina Sevcikova; Bin Yin; Karen L Himmel; Thelma R Tennant; Michelle M Le Beau; David A Largaespada; Scott C Kogan
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

7.  Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.

Authors:  Yuki Kagoya; Akihide Yoshimi; Keisuke Kataoka; Masahiro Nakagawa; Keiki Kumano; Shunya Arai; Hiroshi Kobayashi; Taku Saito; Yoichiro Iwakura; Mineo Kurokawa
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

8.  Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells.

Authors:  Polina Zjablovskaja; Petr Danek; Miroslava Kardosova; Meritxell Alberich-Jorda
Journal:  J Vis Exp       Date:  2018-02-21       Impact factor: 1.355

9.  High expression of LMO2 predicts a favorable outcome in adult patients with BCR/ABL negative B-cell acute lymphoblastic leukemia.

Authors:  Rabab M Aly; Mona M Taalab; Eman M Abdsalam; Omar H Elyamany; Omar E Hasan
Journal:  Oncol Lett       Date:  2016-01-19       Impact factor: 2.967

10.  Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia.

Authors:  Min Ye; Hong Zhang; Henry Yang; Richard Koche; Philipp B Staber; Monica Cusan; Elena Levantini; Robert S Welner; Christian S Bach; Junyan Zhang; Andrei V Krivtsov; Scott A Armstrong; Daniel G Tenen
Journal:  Cell Stem Cell       Date:  2015-09-24       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.